Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Not yet recruiting · NCT07572175 · Registry updated 2026-05-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, immune system disorder, immunoproliferative disorder, injury, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, radiation injury | Not yet recruiting | Phase 2 | 2026-05-07 | NCT07572175 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| American Heart Association | 108 |
| Icahn School of Medicine at Mount Sinai | 256 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |